Inhibikase Therapeutics to Report Full Year 2021 Financial Results on March 31, 2022

BOSTON and ATLANTA, Mar. 25, 2022 /PRNewswire/ — Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics to modify the course of Parkinson’s disease and related disorders, today announced that it will report financial…

No Comments

No comments yet.

Sorry, the comment form is closed at this time.